Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study.

Annals of hematology·2026
Same author

Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.

Frontiers in immunology·2026
Same author

Role of hypertrophic adipocytes, collagen VI, and CD38 in adipose tissue fibrosis in obesity.

Scientific reports·2026
Same author

Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.

Haematologica·2026
Same author

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Haematologica·2026
Same author

A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth.

Blood neoplasia·2026

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

CD38 and bone marrow microenvironment.

Antonella Chillemi1, Gianluca Zaccarello1, Valeria Quarona1

  • 1Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino Medical School, Via Santena 19, 10126 Torino, Italy.

Frontiers in Bioscience (Landmark Edition)
|January 7, 2014
PubMed
Summary
This summary is machine-generated.

CD38, a molecule in bone marrow, plays roles beyond a simple marker in myeloma and CLL. Targeting CD38 with antibodies may improve cancer immunotherapy and patient outcomes.

More Related Videos

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.8K
Tracking Mouse Bone Marrow Monocytes In Vivo
12:08

Tracking Mouse Bone Marrow Monocytes In Vivo

Published on: February 27, 2015

9.3K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.8K
Tracking Mouse Bone Marrow Monocytes In Vivo
12:08

Tracking Mouse Bone Marrow Monocytes In Vivo

Published on: February 27, 2015

9.3K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • CD38 is a molecule involved in the bone marrow microenvironment.
  • Its roles as a receptor and enzyme are often overlooked in clinical settings.
  • CD38 functions within an ectoenzyme network, potentially metabolizing factors like NAD+ and ATP.

Purpose of the Study:

  • To review the multifaceted roles of CD38 in the bone marrow.
  • To explore CD38's involvement in myeloma and chronic lymphocytic leukemia (CLL).
  • To discuss CD38 as a therapeutic target for antibody-mediated treatments.

Main Methods:

  • Literature review of CD38's functions and roles in disease models.
  • Analysis of CD38 as a receptor, enzyme, and part of an ectoenzyme network.
  • Examination of CD38's role in antibody-based therapeutic strategies.

Main Results:

  • CD38 exhibits dual functions as a receptor and enzyme, impacting the bone marrow microenvironment.
  • CD38's involvement in metabolizing soluble factors and influencing hormone secretion is highlighted.
  • CD38 mediates an escape circuit producing adenosine, leading to local anergy.

Conclusions:

  • CD38 is a significant target for antibody-mediated immunotherapy in myeloma and CLL.
  • Blocking CD38 function can disrupt adenosine production and overcome immune suppression.
  • Targeting CD38 offers potential for improved cancer immunotherapy and patient outcomes.